CDK4 and breast cancer: These findings suggest that the combined inhibition of FGFR1/2, CDK4/6, and ER is tolerable at standard doses and may offer clinical benefit in second‐line HR+/FGFR1/2+ BC progression after CDK4/6 inhibitor plus AI therapy [669].